Evaluation of a chimeric (uPA+/+)/SCID mouse model with a humanized liver for prediction of human metabolism

References

• Azuma H, Paulk N, Ranade A, Dorrell C, Al-Dhalimy M, Ellis E, Strom S, Kay MA, Finegold M, Grompe M. (2007). Robust expansion of human hepatocytes in Fah-/-/Rag2-/-/Il2rg-/- mice. Nat Biotechnol 25:903–910.
   PubMed Web of Science ®Google Scholar
• Cheng Z, Herron C, Bowers G, de Serres M. (2006). Assessment of cryopreserved hepatocytes as an alternative to fresh hepatocytes for comparative interspecies metabolism studies with suitable acceptance criteria. Drug Metabolism Letters 1:109–120.
   Google Scholar
• Dear GJ, Roberts AD, Beaumont C, North SE. (2008). Evaluation of preparative high performance liquid chromatography and cryoprobe-nuclear magnetic resonance spectroscopy for the early quantitative estimation of drug metabolites in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 876:182–190.
   PubMed Web of Science ®Google Scholar
• de Serres M, Moss L, Sigafoos J, Sefler A, Castellino S, Bowers G, Serabjit-Singh C. (2010). The disposition and metabolism of GW695634: a non-nucleoside reverse transcriptase inhibitor (NNRTi) for treatment of HIV/AIDS. Xenobiotica 40:437–445.
   PubMed Web of Science ®Google Scholar
• Ekins S, Ring BJ, Grace J, McRobie-Belle DJ, Wrighton SA. (2000). Present and future in vitro approaches for drug metabolism. J Pharmacol Toxicol Methods 44:313–324.
   PubMed Web of Science ®Google Scholar
• Inoue T, Nitta K, Sugihara K, Horie T, Kitamura S, Ohta S. (2008). CYP2C9-catalized metabolism of S-Warfin to 7-Hydroxywarfin in vivo and in vitro in chimeric mice with humanized liver. Drug Metabolism and Disposition 36:2429–2433.
   PubMed Web of Science ®Google Scholar
• Inoue T, Sugihara K, Ohshita H, Horie T, Kitamura S, Ohta S. (2009). Prediction of human disposition toward S-3H-warfarin using chimeric mice with humanized liver. Drug Metab Pharmacokinet 24:153–160.
   PubMed Web of Science ®Google Scholar
• Katoh M, Sawada T, Soeno Y, Nakajima M, Tateno C, Yoshizato K, Yokoi T. (2007). In vivo drug metabolism model for human cytochrome P450 enzyme using chimeric mice with humanized liver. J Pharm Sci 96:428–437.
   PubMed Web of Science ®Google Scholar
• Katoh M, Yokoi T. (2007). Application of chimeric mice with humanized liver for predictive ADME. Drug Metab Rev 39:145–157.
   PubMed Web of Science ®Google Scholar
• Katoh M, Tateno C, Yoshizato K, Yokoi T. (2008). Chimeric mice with humanized liver. Toxicology 246:9–17.
   PubMed Web of Science ®Google Scholar
• Lootens L, Meuleman P, Pozo OJ, Van Eenoo P, Leroux-Roels G, Delbeke FT. (2009). uPA+/+-SCID mouse with humanized liver as a model for in vivo metabolism of exogenous steroids: methandienone as a case study. Clin Chem 55:1783–1793.
   PubMed Web of Science ®Google Scholar
• Meuleman P, Libbrecht L, De Vos R, de Hemptinne B, Gevaert K, Vandekerckhove J, Roskams T, Leroux-Roels G. (2005). Morphological and biochemical characterization of a human liver in a uPA-SCID mouse chimera. Hepatology 41:847–856.
   PubMed Web of Science ®Google Scholar
• Okumura H, Katoh M, Sawada T, Nakajima M, Soeno Y, Yabuuchi H, Ikeda T, Tateno C, Yoshizato K, Yokoi T. (2007). Humanization of excretory pathway in PXB® mice with humanized liver. Toxicological Sciences 97:533–538.
   PubMed Web of Science ®Google Scholar
• Peterson RA, Krull DL, Brown HR, de Serres M. (2010). Morphologic characterization of PhoenixBio (uPA+/+/SCID) humanized liver chimeric mouse model. Drug Metab Lett 4:180–184.
   PubMedGoogle Scholar
• Prous J. (2004). Annual Update 2003/2004 - Treatment of Neurological Disorders. Drugs of the Future 29:253–317.
   Google Scholar
• Romines KR, Freeman GA, Schaller LT, Cowan JR, Gonzales SS, Tidwell JH, Andrews CW 3rd, Stammers DK, Hazen RJ, Ferris RG, Short SA, Chan JH, Boone LR. (2006). Structure-activity relationship studies of novel benzophenones leading to the discovery of a potent, next generation HIV nonnucleoside reverse transcriptase inhibitor. J Med Chem 49:727–739.
   PubMed Web of Science ®Google Scholar
• Suemizua H, Hasegawaa M, Kawaib K, Taniguchia K, Monnaia M, Wakuib M, Suematsuf M, Itoc M, Peltzg G, Nakamurab M. (2008). Establishment of a humanized model of liver using NOD/Shi-SCID IL2Rgnull mice. Biochemical and Biophysical Research Communications 377:248–252.
   PubMedGoogle Scholar
• Sato Y, Yamada H, Iwasaki K, Tateno C, Yokoi T, Yoshizato K, Horii I. (2008). Human hepatocytes can repopulate mouse liver: histopathology of the liver in human hepatocyte-transplanted chimeric mice and toxicologic responses to acetaminophen. Toxicol Pathol 36:581–591.
   PubMed Web of Science ®Google Scholar
• Tateno C, Yoshizane Y, Saito N, Kataoka M, Utoh R, Yamasaki C, Tachibana A, Soeno Y, Asahina K, Hino H, Asahara T, Yokoi T, Furukawa T, Yoshizato K. (2004). Near completely humanized liver in mice shows human-type metabolic responses to drugs. Am J Pathol 165:901–912.
   PubMed Web of Science ®Google Scholar
• Utoh R, Tateno C, Kataoka M, Tachibana A, Masumoto N, Yamasaki C, Shimada T, Itamoto T, Asahara T, Yoshizato K. (2010). Hepatic hyperplasia associated with discordant xenogeneic parenchymal-nonparenchymal interactions in human hepatocyte-repopulated mice. Am J Pathol 177:654–665.
   PubMed Web of Science ®Google Scholar
• Wua J, Chenb Y, Shia X, Gua W. (2009). Dipeptidyl peptidase IV(DPP IV): a novel emerging target for the treatment of type 2 diabetes. Journal of Nanjing Medical University 23:228–235.
   Google Scholar
• Yamazaki H, Kuribayashi S, Inoue T, Tateno C, Nishikura Y, Oofusa K, Harada D, Naito S, Horie T, Ohta S. (2010). Approach for in vivo protein binding of 5-n-butyl-pyrazolo[1,5-a]pyrimidine bioactivated in chimeric mice with humanized liver by two-dimensional electrophoresis with accelerator mass spectrometry. Chem Res Toxicol 23:152–158.
   PubMed Web of Science ®Google Scholar